Máxima Méndez
Research Subjects
Máxima Méndez has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Fernando Wyss
Cardiovascular Services and Technology of Guatemala –CARDIOSOLUTIONS, Guatemala
3 shared publications - Ricardo Lopez Santi
Hospital Italiano de La Plata, La Plata, Argentina
3 shared publications - Adrian Baranchuk
Universidad Abierta Interamericana (UAI)
2 shared publications - Ana Girleza Múnera-Echeverri
Universidad Pontificia Bolivariana
2 shared publications - Ana Isabel Barrientos
23Hospital Bendaña, San Pedro Sula, Honduras
2 shared publications - Ana Verges Castro2 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by Asociacion Costarricense de Cardiología
- Vol. 28 (1)
Consenso Centroamericano y del Caribe para el Manejo de las Dislipidemias: Adaptación de Guias Internacionales a Contextos de Recursos Limitados
La dislipidemia es un factor de riesgo cardiovascular modificable de alta prevalencia en Centroamérica y el Caribe, donde las barreras de acceso a medicamentos y diagnóstico limitan la aplicabilidad directa de guías internacionales. Este consenso fue desarrollado mediante el análisis crítico de las recomendaciones de siete sociedades científicas de referencia, plasmadas en nueve documentos (incluyendo actualizaciones focalizadas) y fue validado por dos paneles independientes (n=15 expertos). El proceso se alineó con la metodología AGREE II, priorizando aplicabilidad regional. Se alcanzó consenso (≥75%) en 58 de 62 recomendaciones. Se recomiendan estatinas de alta intensidad como pilar terapéutico en prevención secundaria, con metas de colesterol LDL <70 mg/dL en alto riesgo y <55 mg/dL en muy alto riesgo, acompañadas de reducción ≥50% desde el valor basal. Si no se alcanzan las metas, se propone añadir ezetimiba y, en casos seleccionados, inhibidores de PCSK9 o icosapento etilo, considerando disponibilidad local. El no-HDL-C se establece como objetivo secundario, especialmente cuando los triglicéridos (TG) superan 150 mg/dL. Se enfatiza la evaluación de determinantes sociales y la creación de unidades integrales de riesgo cardiometabólico para mejorar la adherencia y el control multifactorial. La validación externa confirmó alta pertinencia clínica (83.3% de acuerdo fuerte) y respaldo unánime a la inclusión de poblaciones especiales. Este documento ofrece un marco realista, costo-efectivo y adaptado a los sistemas de salud de Centroamérica y el Caribe, acortando la brecha entre evidencia global y práctica local.Consenso Centroamericano y del Caribe sobre el manejo de Dislipidemias. es una adaptación de las guías clínicas internacionales a nuestra realidad latinoamericana
- 27 October 2026
- Published by Asociacion Costarricense de Cardiología
- Vol. 28 (1)
Open AccessConsenso Centroamericano y del Caribe para el Manejo de las Dislipidemias: Adaptación de Guias Internacionales a Contextos de Recursos Limitados
La dislipidemia es un factor de riesgo cardiovascular modificable de alta prevalencia en Centroamérica y el Caribe, donde las barreras de acceso a medicamentos y diagnóstico limitan la aplicabilidad directa de guías internacionales. Este consenso fue desarrollado mediante el análisis crítico de las recomendaciones de siete sociedades científicas de referencia, plasmadas en nueve documentos (incluyendo actualizaciones focalizadas) y fue validado por dos paneles independientes (n=15 expertos). El proceso se alineó con la metodología AGREE II, priorizando aplicabilidad regional. Se alcanzó consenso (≥75%) en 58 de 62 recomendaciones. Se recomiendan estatinas de alta intensidad como pilar terapéutico en prevención secundaria, con metas de colesterol LDL <70 mg/dL en alto riesgo y <55 mg/dL en muy alto riesgo, acompañadas de reducción ≥50% desde el valor basal. Si no se alcanzan las metas, se propone añadir ezetimiba y, en casos seleccionados, inhibidores de PCSK9 o icosapento etilo, considerando disponibilidad local. El no-HDL-C se establece como objetivo secundario, especialmente cuando los triglicéridos (TG) superan 150 mg/dL. Se enfatiza la evaluación de determinantes sociales y la creación de unidades integrales de riesgo cardiometabólico para mejorar la adherencia y el control multifactorial. La validación externa confirmó alta pertinencia clínica (83.3% de acuerdo fuerte) y respaldo unánime a la inclusión de poblaciones especiales. Este documento ofrece un marco realista, costo-efectivo y adaptado a los sistemas de salud de Centroamérica y el Caribe, acortando la brecha entre evidencia global y práctica local.Consenso Centroamericano y del Caribe sobre el manejo de Dislipidemias. es una adaptación de las guías clínicas internacionales a nuestra realidad latinoamericana
- Open Access
- 14 January 2026
- Published by Ubiquity Press, Ltd. in Global Heart
- Vol. 21 (1) , 81
Immunization and Cardiovascular Disease in Latin America. The CorVacc Study: Sub Analysis by Regions
Introduction: In Latin America, the mortality rate from influenza and pneumococcal disease has increased in recent years. Several challenges limit the implementation of vaccination strategies. These factors contribute to lower-than-expected immunization rates in Latin America. Objective: The objective of this sub-analysis of the Inter-American Registry of Influenza and Pneumococcal Vaccination (CorVacc) is to determine vaccination rates and analyze the factors that influence the North – Central America and Carribean Spanish Speaking (NCC); Andean region (AR) and South Cone (SCR). Methods: A cross-sectional survey of the general population was conducted in 19 Latin American countries. Adults aged 18 and older completed a 34-question online survey. Data were grouped into seven categories: demographic, socioeconomic, and non-demographic. Multivariate logistic regression comparisons were performed between regions to assess the association between vaccination rates and their explanatory variables. Results: Influenza, Pneumococcus and ≥3 doses of COVID-19 vaccination was received by 4,126 (45.18%) CAC, 3,576 (50, 13%) AR and 3,024 (62, 99%) SC; 5,904 (65, 09%) CAC, 5,162 (68, 9%) AR and 3,486 (72, 61%) SC; and 6,266 (68, 61%) CAC, 6,001 (80, 09%) AR and 2,892 (79, 99%), respectively. No association was detected between the regions and the likelihood of receiving the influenza vaccine: AR OR 0.94 (95% CI 0.84–1, 06; p = 0.33), CAC OR 0.81 (CI 0.80–1, 00; p = 0.053). On the contrary, a positive association was detected with Streptococcus pneumoniae vaccination: AR OR 1.12 (CI 1, 01–1, 24; p = 0.032), CAC OR 1.33 (CI 1, 20–1, 47; p < 0.001). A negative association was observed in CAC with COVID-19 ≥ 3 doses vaccination: OR 0.56 (CI 0, 65; p = 0.032; p < 0.001). Social, economic and confidence barriers were identified, but cardiovascular risk factors and comorbidities were not significantly associated with lower vaccination rates. Conclusions: Social, economic, and cultural, but not cardiovascular risk factor or disease variables in Latin American region could explain the lower-than-expected rates of vaccination and the differences observed between regions in vaccination frequencies.
- 14 January 2026
- Published by Ubiquity Press, Ltd. in Global Heart
- Vol. 21 (1) , 81
Open AccessImmunization and Cardiovascular Disease in Latin America. The CorVacc Study: Sub Analysis by Regions
Introduction: In Latin America, the mortality rate from influenza and pneumococcal disease has increased in recent years. Several challenges limit the implementation of vaccination strategies. These factors contribute to lower-than-expected immunization rates in Latin America. Objective: The objective of this sub-analysis of the Inter-American Registry of Influenza and Pneumococcal Vaccination (CorVacc) is to determine vaccination rates and analyze the factors that influence the North – Central America and Carribean Spanish Speaking (NCC); Andean region (AR) and South Cone (SCR). Methods: A cross-sectional survey of the general population was conducted in 19 Latin American countries. Adults aged 18 and older completed a 34-question online survey. Data were grouped into seven categories: demographic, socioeconomic, and non-demographic. Multivariate logistic regression comparisons were performed between regions to assess the association between vaccination rates and their explanatory variables. Results: Influenza, Pneumococcus and ≥3 doses of COVID-19 vaccination was received by 4,126 (45.18%) CAC, 3,576 (50, 13%) AR and 3,024 (62, 99%) SC; 5,904 (65, 09%) CAC, 5,162 (68, 9%) AR and 3,486 (72, 61%) SC; and 6,266 (68, 61%) CAC, 6,001 (80, 09%) AR and 2,892 (79, 99%), respectively. No association was detected between the regions and the likelihood of receiving the influenza vaccine: AR OR 0.94 (95% CI 0.84–1, 06; p = 0.33), CAC OR 0.81 (CI 0.80–1, 00; p = 0.053). On the contrary, a positive association was detected with Streptococcus pneumoniae vaccination: AR OR 1.12 (CI 1, 01–1, 24; p = 0.032), CAC OR 1.33 (CI 1, 20–1, 47; p < 0.001). A negative association was observed in CAC with COVID-19 ≥ 3 doses vaccination: OR 0.56 (CI 0, 65; p = 0.032; p < 0.001). Social, economic and confidence barriers were identified, but cardiovascular risk factors and comorbidities were not significantly associated with lower vaccination rates. Conclusions: Social, economic, and cultural, but not cardiovascular risk factor or disease variables in Latin American region could explain the lower-than-expected rates of vaccination and the differences observed between regions in vaccination frequencies.
- Open Access
- 5 December 2025
- Published by Ubiquity Press, Ltd. in Global Heart
- Vol. 20 (1) , 108
Immunization and Cardiovascular Disease in Latin America. The CorVacc Study: Results
Introduction: Immunization rates against influenza and pneumococcus in Latin America remain lower than expected, particularly in Andean region, Central America, Mexico, and Caribbean region. An incremental correlation between economic strata and educational level and vaccines uptake has been observed. This highlights the need for more comprehensive data to accurately characterize the current health landscape and develop strategies for improvement. Methods and Design: The Inter-American Registry of Influenza and Pneumococcal Vaccination (CorVacc Study) is a cross-sectional survey of the general population conducted across 19 Latin American countries. Adults aged 18 years and older completed a 34-question online survey. The pool was validated within the first 1000 responses. Data were grouped into seven categories: demographics, socioeconomic and educational level, cardiometabolic profile, cardiovascular interventions, medical follow-up and treatments, and COVID-19 vaccination status. Results: A total of 21,389 responses were obtained, distributed as follows: 8915 from the North, Central, and Caribbean region; 7492 from the Andean region; and 4801 from the Southern Cone region. Influenza vaccination rates were lower in the Andean region (OR: 0.62; 95% CI: 0.50–0.78), the Caribbean (OR: 0.30; 95% CI: 0.23–0.39), and Central America (OR: 0.59; 95% CI: 0.46–0.76) compared with the Southern Cone. Residing in Central America (OR: 3.06; 95% CI: 1.62–5.77) was associated with greater pneumococcal vaccination. The probability of being vaccinated against influenza was higher in men (OR: 1.3; 95% CI: 1.1–1.6) and in individuals with obesity (OR: 1.26; 95% CI: 1.13–1.40). COPD was associated with a lower probability of pneumococcal vaccination (OR: 0.51; 95% CI: 0.33–0.79). Conclusions: This study highlights the importance of targeted vaccination campaigns to improve coverage, particularly in regions with lower rates. It also underscores the need for enhanced education and awareness of the benefits of vaccination. Tackling barriers such as vaccine hesitancy and misinformation will be essential for raising vaccination rates and, ultimately, for reducing the burden of cardiovascular disease.
- 5 December 2025
- Published by Ubiquity Press, Ltd. in Global Heart
- Vol. 20 (1) , 108
Open AccessImmunization and Cardiovascular Disease in Latin America. The CorVacc Study: Results
Introduction: Immunization rates against influenza and pneumococcus in Latin America remain lower than expected, particularly in Andean region, Central America, Mexico, and Caribbean region. An incremental correlation between economic strata and educational level and vaccines uptake has been observed. This highlights the need for more comprehensive data to accurately characterize the current health landscape and develop strategies for improvement. Methods and Design: The Inter-American Registry of Influenza and Pneumococcal Vaccination (CorVacc Study) is a cross-sectional survey of the general population conducted across 19 Latin American countries. Adults aged 18 years and older completed a 34-question online survey. The pool was validated within the first 1000 responses. Data were grouped into seven categories: demographics, socioeconomic and educational level, cardiometabolic profile, cardiovascular interventions, medical follow-up and treatments, and COVID-19 vaccination status. Results: A total of 21,389 responses were obtained, distributed as follows: 8915 from the North, Central, and Caribbean region; 7492 from the Andean region; and 4801 from the Southern Cone region. Influenza vaccination rates were lower in the Andean region (OR: 0.62; 95% CI: 0.50–0.78), the Caribbean (OR: 0.30; 95% CI: 0.23–0.39), and Central America (OR: 0.59; 95% CI: 0.46–0.76) compared with the Southern Cone. Residing in Central America (OR: 3.06; 95% CI: 1.62–5.77) was associated with greater pneumococcal vaccination. The probability of being vaccinated against influenza was higher in men (OR: 1.3; 95% CI: 1.1–1.6) and in individuals with obesity (OR: 1.26; 95% CI: 1.13–1.40). COPD was associated with a lower probability of pneumococcal vaccination (OR: 0.51; 95% CI: 0.33–0.79). Conclusions: This study highlights the importance of targeted vaccination campaigns to improve coverage, particularly in regions with lower rates. It also underscores the need for enhanced education and awareness of the benefits of vaccination. Tackling barriers such as vaccine hesitancy and misinformation will be essential for raising vaccination rates and, ultimately, for reducing the burden of cardiovascular disease.
- Open Access
- 26 March 2024
- Published by Federacion Argentina de Cardiología in Revista de la Federación Argentina de Cardiología
- Vol. 53 (1) , 5-8
Nuevas metas terapéuticas en el tratamiento de las dislipemias: colesterol no HDL y remanentes de colesterol
Non-HDL-C is a powerful indicator of lipoproteins rich in ApoB. Its measurement is much simpler, it does not require fasting to quantify it, not being influenced by triglyceride levels, and it is an excellent marker of atherogenic cholesterol, with a better correlation with cardiovascular risk than LDL-C. In patients in high risk of atherogenic dyslipidemia, the strategy of consideringnon-HDL-C as a primary objective is allowed, because it incorporates the risk of lipid origin better than LDL-C and because it is more feasible than measuring ApoB. The therapeutic objective of non-HDL-C is to add 30 mg/dL to the calculated LDL-C target value; in the general population, optimal non-HDL-C levels of less than 130 mg/dL are maintained. In a patient considered in very high risk, the target LDL-C is less than 55 mg/dL; thus their non-HDL-C should not exceed 85 mg/dL. Non-HDL cholesterol becomes an excellent indicator of total atherogenic cholesterol. And it is a primary therapeutic objective in individuals with atherogenic dyslipidemia. Evidence available to date shows the benefit of adding ethyl eicosapentaenoic acid to patients with elevatednon-HDL cholesterol under optimal treatment with statins, for reducing cardiovascular risk. Fibrates may be considered in patients with extreme hypertriglyceridemia.
- 26 March 2024
- Published by Federacion Argentina de Cardiología in Revista de la Federación Argentina de Cardiología
- Vol. 53 (1) , 5-8
Open AccessNuevas metas terapéuticas en el tratamiento de las dislipemias: colesterol no HDL y remanentes de colesterol
Non-HDL-C is a powerful indicator of lipoproteins rich in ApoB. Its measurement is much simpler, it does not require fasting to quantify it, not being influenced by triglyceride levels, and it is an excellent marker of atherogenic cholesterol, with a better correlation with cardiovascular risk than LDL-C. In patients in high risk of atherogenic dyslipidemia, the strategy of consideringnon-HDL-C as a primary objective is allowed, because it incorporates the risk of lipid origin better than LDL-C and because it is more feasible than measuring ApoB. The therapeutic objective of non-HDL-C is to add 30 mg/dL to the calculated LDL-C target value; in the general population, optimal non-HDL-C levels of less than 130 mg/dL are maintained. In a patient considered in very high risk, the target LDL-C is less than 55 mg/dL; thus their non-HDL-C should not exceed 85 mg/dL. Non-HDL cholesterol becomes an excellent indicator of total atherogenic cholesterol. And it is a primary therapeutic objective in individuals with atherogenic dyslipidemia. Evidence available to date shows the benefit of adding ethyl eicosapentaenoic acid to patients with elevatednon-HDL cholesterol under optimal treatment with statins, for reducing cardiovascular risk. Fibrates may be considered in patients with extreme hypertriglyceridemia.
- Open Access
- 5 January 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (2) , 314
Central American and Caribbean Consensus Document for the Optimal Management of Oral Anticoagulation in Patients with Non-Valvular Atrial Fibrillation Endorsed by the Central American and Caribbean Society of Arterial Hypertension and Cardiovascular Prevention
Atrial fibrillation (AF) is the most common arrhythmia in adults. Prevention of the ischaemic risk with oral anticoagulants (OACs) is widely recommended, and current clinical guidelines recommend direct oral anticoagulants (DOACs) as preference therapy for stroke prevention. However, there are currently no clinical practice guidelines or recommendation documents on the optimal management of OACs in patients with AF that specifically address and adapt to the Central American and Caribbean context. The aim of this Delphi-like study is to respond to doubts that may arise in the management of OACs in patients with non-valvular AF in this geographical area. A consensus project was performed on the basis of a systematic review of the literature, a recommended ADOLOPMENT-like approach, and the application of a two-round Delphi survey. In the first round, 31 recommendations were evaluated and 30 reached consensus, of which, 10 unanimously agreed. The study assessed expert opinions in a wide variety of contextualized recommendations for the optimal management of DOACs in patients with non-valvular atrial fibrillation (NVAF). There is a broad consensus on the clinical practice guideline (CPG) statements used related to anticoagulation indication, patient follow-up, anticoagulation therapy complications, COVID-19 management and prevention, and cardiac interventions.
- 5 January 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (2) , 314
Open AccessCentral American and Caribbean Consensus Document for the Optimal Management of Oral Anticoagulation in Patients with Non-Valvular Atrial Fibrillation Endorsed by the Central American and Caribbean Society of Arterial Hypertension and Cardiovascular Prevention
Atrial fibrillation (AF) is the most common arrhythmia in adults. Prevention of the ischaemic risk with oral anticoagulants (OACs) is widely recommended, and current clinical guidelines recommend direct oral anticoagulants (DOACs) as preference therapy for stroke prevention. However, there are currently no clinical practice guidelines or recommendation documents on the optimal management of OACs in patients with AF that specifically address and adapt to the Central American and Caribbean context. The aim of this Delphi-like study is to respond to doubts that may arise in the management of OACs in patients with non-valvular AF in this geographical area. A consensus project was performed on the basis of a systematic review of the literature, a recommended ADOLOPMENT-like approach, and the application of a two-round Delphi survey. In the first round, 31 recommendations were evaluated and 30 reached consensus, of which, 10 unanimously agreed. The study assessed expert opinions in a wide variety of contextualized recommendations for the optimal management of DOACs in patients with non-valvular atrial fibrillation (NVAF). There is a broad consensus on the clinical practice guideline (CPG) statements used related to anticoagulation indication, patient follow-up, anticoagulation therapy complications, COVID-19 management and prevention, and cardiac interventions.
- 28 October 2022
- Published by Universidad del Pacifico - Paraguay in Revista científica ciencias de la salud
- Vol. 4 (2) , 43-49
Situación de salud cardiovascular en la Republica Dominicana
Introduction: Cardiovascular health comprises a set of variables that interact with each other (between non-modifiable factors and modifiable factors) to modify the risk of suffering a cardiovascular event (CVD). Material and Methods: An online survey based on Google Forms was conducted to measure cardiovascular health in the adult population in the Dominican Republic. A questionnaire prepared by the authors based on the DUCTH criteria for hypercholesterolemia was used. Results: The sociodemographic characteristics of the participants were heterogeneous, 60% of the participants had a pathological family history, 55% were physical inactive, observing 70% had no or minimum intake of yogurt, same behavior was observed in 44% of the sample related to milk intake, yet 94% had a frequent intake of meat. Conclusion: The cardiovascular health of Dominicans has a lower quality associated with a higher consumption of meat and tobacco and a lower amount of exercise; This behavior may have been influenced by the COVID-19 pandemic or the characteristics of the region.
- 28 October 2022
- Published by Universidad del Pacifico - Paraguay in Revista científica ciencias de la salud
- Vol. 4 (2) , 43-49
Situación de salud cardiovascular en la Republica Dominicana
Introduction: Cardiovascular health comprises a set of variables that interact with each other (between non-modifiable factors and modifiable factors) to modify the risk of suffering a cardiovascular event (CVD). Material and Methods: An online survey based on Google Forms was conducted to measure cardiovascular health in the adult population in the Dominican Republic. A questionnaire prepared by the authors based on the DUCTH criteria for hypercholesterolemia was used. Results: The sociodemographic characteristics of the participants were heterogeneous, 60% of the participants had a pathological family history, 55% were physical inactive, observing 70% had no or minimum intake of yogurt, same behavior was observed in 44% of the sample related to milk intake, yet 94% had a frequent intake of meat. Conclusion: The cardiovascular health of Dominicans has a lower quality associated with a higher consumption of meat and tobacco and a lower amount of exercise; This behavior may have been influenced by the COVID-19 pandemic or the characteristics of the region.
- 28 October 2022
- Published by Universidad del Pacifico - Paraguay in Revista científica ciencias de la salud
- Vol. 4 (2) , 38-42
Conocimiento sobre hipercolesterolemia familiar por el personal de salud en República Dominicana
Introducción. La hipercolesterolemia familiar (HcF) es una patología causada por diversas mutaciones con una incidencia variable dependiendo de su forma heterocigota u homocigota. Sin embargo, pocos casos son diagnosticados y no todo el personal de salud conoce sobre la enfermedad. Materiales y Método. Se realizó una encuesta en línea basada en Google Forms para medir el nivel de conocimiento del personal de salud sobre la HcF en la República Dominicana. Se utilizó un cuestionario confeccionado por los autores basado en los criterios DUCTH de hipercolesterolemia. Resultados. El predominio del personal de salud que llenó el cuestionario fue de nutriólogos; el conocimiento sobre los valores de corte adecuado para el diagnóstico de HcF fue reportado en 30% de la muestra. Conclusiones. Es imperativo incrementar el conocimiento del personal de salud sobre HcF con el objetivo de disminuir la muerte cardiovascular prematura.
- 28 October 2022
- Published by Universidad del Pacifico - Paraguay in Revista científica ciencias de la salud
- Vol. 4 (2) , 38-42
Conocimiento sobre hipercolesterolemia familiar por el personal de salud en República Dominicana
Introducción. La hipercolesterolemia familiar (HcF) es una patología causada por diversas mutaciones con una incidencia variable dependiendo de su forma heterocigota u homocigota. Sin embargo, pocos casos son diagnosticados y no todo el personal de salud conoce sobre la enfermedad. Materiales y Método. Se realizó una encuesta en línea basada en Google Forms para medir el nivel de conocimiento del personal de salud sobre la HcF en la República Dominicana. Se utilizó un cuestionario confeccionado por los autores basado en los criterios DUCTH de hipercolesterolemia. Resultados. El predominio del personal de salud que llenó el cuestionario fue de nutriólogos; el conocimiento sobre los valores de corte adecuado para el diagnóstico de HcF fue reportado en 30% de la muestra. Conclusiones. Es imperativo incrementar el conocimiento del personal de salud sobre HcF con el objetivo de disminuir la muerte cardiovascular prematura.
- Open Access
Influenza and Pneumococcal Vaccination in Non-Infected Cardiometabolic Patients from the Americas during the COVID-19 Pandemic. A Sub-Analysis of the CorCOVID-LATAM Study
Background: Influenza vaccination (IV) and Pneumococcus vaccination (PV) are recommended for patients with cardiometabolic diseases. This study aimed to evaluate the immunization rate of ambulatory cardiometabolic patients during the COVID-19 pandemic in the Americas. Methods: Electronic surveys were collected from 13 Spanish speaking countries between 15 June and 15 July 2020. Results: 4216 patients were analyzed. Mean age 60 (±15) years and 49% females. Global IV rate was 46.5% and PV 24.6%. Vaccinated patients were older (IV = 63 vs. 58 years; PV = 68 vs. 59, p < 0.01) but without gender difference. Vaccination rates were greater in higher-risk groups (65+, diabetics, heart failure), but not in coronary artery disease patients. In the Southern cone, the rate of IV and PV was approximately double that in the tropical regions of the Americas. In a multivariate model, geographic zone (IV = OR 2.02, PV = OR 2.42, p < 0.001), age (IV = OR 1.023, PV = OR 1.035, p < 0.001), and incomes (IV = OR 1.28, PV = OR 1.58, p < 0.001) were predictors for vaccination. Conclusions: During the COVID-19 pandemic, ambulatory patients with cardiometabolic diseases from the Americas with no evidence of COVID-19 infection had lower-than-expected rates of IV and PV. Geographic, social, and cultural differences were found, and they should be explored in depth.
Open AccessInfluenza and Pneumococcal Vaccination in Non-Infected Cardiometabolic Patients from the Americas during the COVID-19 Pandemic. A Sub-Analysis of the CorCOVID-LATAM Study
Background: Influenza vaccination (IV) and Pneumococcus vaccination (PV) are recommended for patients with cardiometabolic diseases. This study aimed to evaluate the immunization rate of ambulatory cardiometabolic patients during the COVID-19 pandemic in the Americas. Methods: Electronic surveys were collected from 13 Spanish speaking countries between 15 June and 15 July 2020. Results: 4216 patients were analyzed. Mean age 60 (±15) years and 49% females. Global IV rate was 46.5% and PV 24.6%. Vaccinated patients were older (IV = 63 vs. 58 years; PV = 68 vs. 59, p < 0.01) but without gender difference. Vaccination rates were greater in higher-risk groups (65+, diabetics, heart failure), but not in coronary artery disease patients. In the Southern cone, the rate of IV and PV was approximately double that in the tropical regions of the Americas. In a multivariate model, geographic zone (IV = OR 2.02, PV = OR 2.42, p < 0.001), age (IV = OR 1.023, PV = OR 1.035, p < 0.001), and incomes (IV = OR 1.28, PV = OR 1.58, p < 0.001) were predictors for vaccination. Conclusions: During the COVID-19 pandemic, ambulatory patients with cardiometabolic diseases from the Americas with no evidence of COVID-19 infection had lower-than-expected rates of IV and PV. Geographic, social, and cultural differences were found, and they should be explored in depth.